FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2937508081> ?p ?o ?g. }

• W2937508081 endingPage "115" @default.
• W2937508081 startingPage "101" @default.
• W2937508081 abstract "Programmed cell death-1/programmed cell death ligand-1 (PD-1/PDL-1) inhibitors are the newest class of approved drugs for advanced urothelial cancer (AdUC). This review aims to collate the evidence for their efficacy and safety in various treatment settings.Extensive search of databases was performed (updated May 2018) and the protocol was registered on PROSPERO (CRD42017081568). The review was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analysis statement. STATA (v 12) and Revman 5.3.5 were used for data analysis.Ten nonrandomized, open-label clinical trials were included in this review. PD-1/PD-L1 inhibitors were used as second-line, stand-alone in eight trials and as first-line in cisplatin-ineligible in two trials. Heterogeneity was observed for study design, PDL-1 testing methods, cutoff criterias used and translational markers evaluated. The pooled objective response rate (ORR) was 18.2% (95% confidence interval [CI] 15.1-21.2, n = 1785) with PD-1/PDL-1 inhibitors in second-line settings as compared to 12.6% (95% CI 10.3-14.9, n = 736) with second-line chemotherapy and 23.7% (95% CI 19.9-27.4, n = 489) with PD-1/PDL-1 inhibitors as first-line therapy in cisplatin-ineligible patients. The median progression-free survival and overall survival was similar with PD-1/PD-L1 inhibitors in both second- and first-line treatment settings (1.5-2.9 vs. 2.0-2.7 months and 7.9-18.2 vs. 15.9 months) and second-line chemotherapy (3.3-4.0 months and 7.4-8 months). Odds of achieving ORR was 0.10 (95% CI 0.03-0.31, n = 229) in the second-line, stand-alone setting with a combined positive score (CPS) cutoff of 25% and was 0.34 (95% CI 0.19-0.62, n = 265) with a CPS cut-off of 10% in first-line setting in the cisplatin-ineligible.PD-1/PDL-1 inhibitors appear to be promising in the treatment of AdUC and CPS may be a potentially reliable biomarker for predicting response but needs validation. Caution needs to be exercised until more data are available on imAEs and further studies are required to prove their worth as the standard of care." @default.
• W2937508081 created "2019-04-25" @default.
• W2937508081 creator A5013684854 @default.
• W2937508081 creator A5038644822 @default.
• W2937508081 creator A5059547897 @default.
• W2937508081 creator A5061424807 @default.
• W2937508081 creator A5071691142 @default.
• W2937508081 creator A5072585514 @default.
• W2937508081 creator A5077401384 @default.
• W2937508081 date "2019-04-20" @default.
• W2937508081 modified "2023-10-17" @default.
• W2937508081 title "Efficacy and safety of programmed cell death-1/programmed cell death ligand-1 inhibitors in advanced urothelial malignancy: A systematic review and meta-analysis." @default.
• W2937508081 cites W1757407923 @default.
• W2937508081 cites W1814430027 @default.
• W2937508081 cites W1858135205 @default.
• W2937508081 cites W1971208896 @default.
• W2937508081 cites W1993289360 @default.
• W2937508081 cites W2022465587 @default.
• W2937508081 cites W2092977595 @default.
• W2937508081 cites W2096322385 @default.
• W2937508081 cites W2098923148 @default.
• W2937508081 cites W2102116016 @default.
• W2937508081 cites W2136859769 @default.
• W2937508081 cites W2147328441 @default.
• W2937508081 cites W2148562299 @default.
• W2937508081 cites W2161765043 @default.
• W2937508081 cites W2289712604 @default.
• W2937508081 cites W2401835169 @default.
• W2937508081 cites W2414977199 @default.
• W2937508081 cites W2527802349 @default.
• W2937508081 cites W2530516001 @default.
• W2937508081 cites W2531269403 @default.
• W2937508081 cites W2532281454 @default.
• W2937508081 cites W2557730509 @default.
• W2937508081 cites W2559804019 @default.
• W2937508081 cites W2560367415 @default.
• W2937508081 cites W2570159314 @default.
• W2937508081 cites W2582671354 @default.
• W2937508081 cites W2584071843 @default.
• W2937508081 cites W2588681363 @default.
• W2937508081 cites W2588916311 @default.
• W2937508081 cites W2604441970 @default.
• W2937508081 cites W2615188404 @default.
• W2937508081 cites W2733672984 @default.
• W2937508081 cites W2745624257 @default.
• W2937508081 cites W2760661635 @default.
• W2937508081 cites W2777192533 @default.
• W2937508081 cites W2783137027 @default.
• W2937508081 cites W2892952396 @default.
• W2937508081 cites W2897581535 @default.
• W2937508081 cites W2917837889 @default.
• W2937508081 cites W4246715702 @default.
• W2937508081 doi "https://doi.org/10.4103/iju.iju_357_18" @default.
• W2937508081 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6458809" @default.
• W2937508081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31000914" @default.
• W2937508081 hasPublicationYear "2019" @default.
• W2937508081 type Work @default.
• W2937508081 sameAs 2937508081 @default.
• W2937508081 citedByCount "0" @default.
• W2937508081 crossrefType "journal-article" @default.
• W2937508081 hasAuthorship W2937508081A5013684854 @default.
• W2937508081 hasAuthorship W2937508081A5038644822 @default.
• W2937508081 hasAuthorship W2937508081A5059547897 @default.
• W2937508081 hasAuthorship W2937508081A5061424807 @default.
• W2937508081 hasAuthorship W2937508081A5071691142 @default.
• W2937508081 hasAuthorship W2937508081A5072585514 @default.
• W2937508081 hasAuthorship W2937508081A5077401384 @default.
• W2937508081 hasConcept C126322002 @default.
• W2937508081 hasConcept C143998085 @default.
• W2937508081 hasConcept C207103383 @default.
• W2937508081 hasConcept C2779399171 @default.
• W2937508081 hasConcept C44249647 @default.
• W2937508081 hasConcept C535046627 @default.
• W2937508081 hasConcept C71924100 @default.
• W2937508081 hasConcept C95190672 @default.
• W2937508081 hasConceptScore W2937508081C126322002 @default.
• W2937508081 hasConceptScore W2937508081C143998085 @default.
• W2937508081 hasConceptScore W2937508081C207103383 @default.
• W2937508081 hasConceptScore W2937508081C2779399171 @default.
• W2937508081 hasConceptScore W2937508081C44249647 @default.
• W2937508081 hasConceptScore W2937508081C535046627 @default.
• W2937508081 hasConceptScore W2937508081C71924100 @default.
• W2937508081 hasConceptScore W2937508081C95190672 @default.
• W2937508081 hasIssue "2" @default.
• W2937508081 hasLocation W29375080811 @default.
• W2937508081 hasOpenAccess W2937508081 @default.
• W2937508081 hasPrimaryLocation W29375080811 @default.
• W2937508081 hasRelatedWork W2090763189 @default.
• W2937508081 hasRelatedWork W2154948599 @default.
• W2937508081 hasRelatedWork W2516062397 @default.
• W2937508081 hasRelatedWork W2792916732 @default.
• W2937508081 hasRelatedWork W2793335702 @default.
• W2937508081 hasRelatedWork W2913113213 @default.
• W2937508081 hasRelatedWork W2914671834 @default.
• W2937508081 hasRelatedWork W3114266572 @default.
• W2937508081 hasRelatedWork W4210646467 @default.
• W2937508081 hasRelatedWork W4254083861 @default.
• W2937508081 hasVolume "35" @default.

• next